Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD study of CEL383 in healthy volunteers
NCT05901883Phase 1Completed
- Sponsor
- Celsius Therapeutics
- Start
- Jun 2023
- Primary completion
- Jan 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in inflammatory bowel disease (IBD) comparing CEL383 Arm with Placebo Arm (2 arms). Primary endpoint: Treatment-emergent adverse events. Started Jun 2023; status: completed.
02
Drugs
CEL383
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT05901883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05901883.